SAB Biotherapeutics, Inc. Balance Sheet
SABS|5 years of annual SEC 10-K data (FY2021-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 5 fiscal years. All figures from audited SEC 10-K filings.
SAB Biotherapeutics, Inc. had $173M in total assets and $26M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | $10.5M | $8.9M | $56.6M | $33.2M | $12.6M |
| Accounts Receivable | - | - | - | $8.0M | $8.0M |
| Current Assets | $101.1M | $23.8M | $58.9M | $50.2M | $34.5M |
| PP&E (Net) | $13.3M | $15.4M | $19.7M | $24.3M | $14.8M |
| Total Assets | $172.8M | $44.2M | $83.9M | $81.1M | $56.5M |
| Current Liabilities | $10.7M | $8.0M | $10.8M | $26.5M | $11.1M |
| Shareholders' Equity | $26.0M | $57.3M | $31.1M | $39.0M | $7.7M |